Proteomic analysis revealed that the levels of PARK7 are increased in several types of cancer, and O-acetylglucosamine (GlcNAc)-modified PARK7 is involved in the pathogenesis of colorectal cancer (CRC) and human scirrhous-type gastric carcinoma (GC) [63,64,65,66]. Here, PARK7 is linked to colorectal cancer.